Amani Therapeutics
Developing highly efficacious, safer medicines.
About
Amani Therapeutics is a biotechnology company focused on developing highly efficacious, safer medicines for people living with various conditions. The company was founded with backing from RTW Investments and has in-licensed a Phase 3-ready novel chemical entity (NCE) from AstraZeneca as part of its lead program, AM-01.
Similar companies
Moderna is a biotechnology company pioneering mRNA medicine, best known for its COVID-19 vaccine and a broad pipeline of mRNA-based therapeutics.
Shares Biotechnology, Pharmaceuticals
Biotechnology company focused on developing cancer immunotherapies.
Shares Biotechnology, Pharmaceuticals
Biotechnology company developing and commercializing cell therapies for cancer treatment.
Shares Biotechnology, Pharmaceuticals
Biotechnology company developing transformative gene-based medicines using CRISPR/Cas9 gene editing technology.
Shares Biotechnology, Pharmaceuticals
Developing novel therapeutics to restore gut lymphatic function.
Shares Biotechnology, Pharmaceuticals
Clinical-stage biotechnology company advancing molecular glue degrader (MGD) medicines.
Shares Biotechnology, Pharmaceuticals
Key facts
- Headquarters
- New York, USA
- Total funding
- $25M (Series A)
Funding rounds
| Date | Round | Amount | Lead investors |
|---|---|---|---|
| 23 Mar 2026 | Series A | $25M |
Frequently asked
How much funding has Amani Therapeutics raised?
Amani Therapeutics has raised a total of $25M in funding. The most recent round on record is Series A.
Public record
SEC filings, insider activity, nonprofit links and pay benchmarks for Amani Therapeutics
